Monte Rosa Therapeutics (GLUE) to Post Earnings on Thursday

Monte Rosa Therapeutics (NASDAQ:GLUE) is expected to be announcing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.3657) per share and revenue of $12.9140 million for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 7, 2026 at 9:30 AM ET.

Monte Rosa Therapeutics (NASDAQ:GLUE) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative return on equity of 40.99% and a negative net margin of 302.69%.The company had revenue of $4.21 million during the quarter, compared to the consensus estimate of $10.95 million. On average, analysts expect Monte Rosa Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Monte Rosa Therapeutics Trading Down 2.4%

Shares of NASDAQ GLUE opened at $21.52 on Thursday. The firm has a fifty day simple moving average of $20.85 and a two-hundred day simple moving average of $19.66. Monte Rosa Therapeutics has a 12 month low of $4.12 and a 12 month high of $25.77. The firm has a market capitalization of $1.82 billion, a PE ratio of -14.54 and a beta of 1.56.

Analyst Ratings Changes

Several equities analysts recently issued reports on GLUE shares. Guggenheim boosted their price target on shares of Monte Rosa Therapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. Jefferies Financial Group restated a “buy” rating on shares of Monte Rosa Therapeutics in a report on Monday. Zacks Research cut Monte Rosa Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, July 6th. Weiss Ratings upgraded Monte Rosa Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday. Finally, JPMorgan Chase & Co. raised their price objective on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Seven investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, Monte Rosa Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.83.

Insider Buying and Selling at Monte Rosa Therapeutics

In other news, insider Filip Janku sold 5,407 shares of Monte Rosa Therapeutics stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $24.50, for a total transaction of $132,471.50. Following the completion of the transaction, the insider directly owned 60,612 shares in the company, valued at approximately $1,484,994. This trade represents a 8.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Sharon Townson sold 6,000 shares of the business’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $23.31, for a total value of $139,860.00. Following the completion of the sale, the insider directly owned 67,845 shares in the company, valued at approximately $1,581,466.95. This represents a 8.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 81,778 shares of company stock worth $1,768,581. Insiders own 6.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC boosted its holdings in Monte Rosa Therapeutics by 56.6% in the fourth quarter. Virtu Financial LLC now owns 18,717 shares of the company’s stock worth $293,000 after acquiring an additional 6,765 shares in the last quarter. Invesco Ltd. grew its stake in shares of Monte Rosa Therapeutics by 270.0% in the fourth quarter. Invesco Ltd. now owns 362,213 shares of the company’s stock worth $5,680,000 after acquiring an additional 264,315 shares during the last quarter. Mercer Global Advisors Inc. ADV purchased a new stake in shares of Monte Rosa Therapeutics in the fourth quarter worth $172,000. Empowered Funds LLC increased its holdings in shares of Monte Rosa Therapeutics by 218.0% during the fourth quarter. Empowered Funds LLC now owns 278,077 shares of the company’s stock valued at $4,360,000 after acquiring an additional 190,627 shares in the last quarter. Finally, Voloridge Investment Management LLC bought a new position in shares of Monte Rosa Therapeutics during the fourth quarter valued at $561,000. Institutional investors own 79.96% of the company’s stock.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.